3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorouracil
128
Leucovorin
120
Oxaliplatin
101
Irinotecan
89
Bevacizumab
55
Cetuximab
44
Capecitabine
40
Folfox protocol
29
Panitumumab
22
Colonoscopy
17
Chemotherapy, Adjuvant
16
Floxuridine
15
Early Intervention, Educational
15
Erlotinib Hydrochloride
13
Surveys and Questionnaires
11
IFL protocol
11
Counseling
11
Celecoxib
11
Immunohistochemistry
10
Gemcitabine
10
Psychiatric Rehabilitation
9
Methods
8
Magnetic Resonance Spectroscopy
8
Gene Expression Profiling
8
Exercise
8
Dexamethasone
8
sargramostim
7
Sorafenib
7
Radiotherapy
7
Nivolumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colonic Neoplasms
×
Tinzaparin
×
Clear all
NCT01455831
2021-05-17
PERIOP-01
Ottawa Hospital Research Institute
Phase 3
Completed
616 enrolled